Simbec-Orion Group
Company
Simbec-Orion Group develops one asset, in phase 2 (Zelasudil in fibrosis). Mostly small molecule acting on inflammation, ROCK2 and MAP4K4.
- 1
- Asset
- Furthest stage
- Phase 2
- 0
- Trials
- 0
- Signals
Pipeline
1Selective ROCK2 inhibitor
Phase 2, Small molecule, Inflammation, ROCK2, fibrosis, idiopathic pulmonary fibrosis, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials3
- Similar companies6